A European consortium has been awarded a grant of up to €1m to develop a blood-based multi-omics test to predict response to immune checkpoint inhibitors in cancer.
The collaboration is made up of Novigenix, PamGene International and Radboud University.
Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic cancer. Although ICIs are highly effective with durable results in some patients, only a minority respond and benefit from ICIs.
The aim of the consortium is to develop a novel in vitro diagnostic (IVD) liquid biopsy test for accurate prediction of response to ICIs, leveraging a unique multi-omics approach of combining mRNA and kinase activity profiling.
The biomarker development strategy is based on whole blood transcriptome and kinome profiling technologies. The consortium will take advantage of advanced machine learning methods to develop and validate the AI-based multi-omics signatures.
Eurostars, which supports international innovative projects led by R&D-performing SMEs, is behind the funding.
Dr Brian Hashemi, executive chairman of Novigenix, said: “This Eurostars project combines excellent, world-leading science and technologies in a consortium dedicated to developing the first high performance multi-modal liquid biopsy test for the prediction of anti-PD1 response in UC patients.
“The high Eurostars review score placed the project in the top 5% of its peers, and we believe its completion can significantly improve
NHS Forth Valley goes live with RCPCH GrowthAPI integrated with Morse Mobile EPR
Mid and South Essex ICS building new shared care record with Orion Health
Red light can reduce blood glucose levels, study finds
Medical device design standards
Why rethinking funding priorities is key to virtual ward success
Thousands with cancer-causing condition offered life-saving NHS bowel cancer test
Neuromelanin imaging: A new path to brain health insights
Lenus puts automation at heart of diagnostic pathways with CDC Heart Failure roll-out
Gallery will highlight therapeutic power of art
Delays in lockdown skin cancer diagnosis linked to deaths and £6bn costs in Europe
- Insight4 weeks ago
8 tips to brand your new medical device
- Diagnostics3 weeks ago
NHS England launches gene testing programme to identify cancer risk early
- AI6 days ago
Aim AI policies at hardware to ensure safety, experts say
- Robotics4 weeks ago
Synthesis robot harnesses AI to speed up chemical discovery